The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2014
Effect of dopamine infusion on thyroid hormone tests and prolactin levels in very low birth weight infants.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ekmen Sadrettin, Degirmencioglu Halil, Uras Nurdan, Oncel Mehmet Yekta, Sari Fatma Nur, Canpolat Fuat Emre, Oguz Suna Serife, Dilmen Ugur
Аннотация
OBJECTIVE: To evaluate the effect of dopamine on thyroid hormone tests and prolactin (PRL) and to assess requirement for L-thyroxin (LT4).
METHODS: The infants (n = 102) were divided into three groups (Group 1; received no dopamine, Group 2 received ≤25 mg/kg cumulative dose and Group 3; received >25 mg/kg cumulative dose). Blood samples were taken at 6-8 days (timepoint 1), 13-15 days (timepoint 2), and 4-6 weeks of life (timepoint 3).
RESULTS: Respiratory distress syndrome was higher in group 2 and 3. Patnet ductus arteriosus was higher in group 3 than in groups 1 and 2. Duration and cumulative dose in group 3 were higher than group 2. There was no difference between thyroid hormones that were taken after stopping infusion at timepoint 3 among all groups. No therapy with LT4 was needed. PRL levels were higher at timepoint 1 in group 1 than compared to group 2 and 3 (p < 0.05), and no difference between group 2 and 3 (p > 0.05). This difference was disappeared at following timepoints.
CONCLUSIONS: The release of TSH, FT3, FT4 and PRL were not inhibited and prophylactic thyroid hormone treatment was not required in VLBW infants receiving dopamine infusions.
METHODS: The infants (n = 102) were divided into three groups (Group 1; received no dopamine, Group 2 received ≤25 mg/kg cumulative dose and Group 3; received >25 mg/kg cumulative dose). Blood samples were taken at 6-8 days (timepoint 1), 13-15 days (timepoint 2), and 4-6 weeks of life (timepoint 3).
RESULTS: Respiratory distress syndrome was higher in group 2 and 3. Patnet ductus arteriosus was higher in group 3 than in groups 1 and 2. Duration and cumulative dose in group 3 were higher than group 2. There was no difference between thyroid hormones that were taken after stopping infusion at timepoint 3 among all groups. No therapy with LT4 was needed. PRL levels were higher at timepoint 1 in group 1 than compared to group 2 and 3 (p < 0.05), and no difference between group 2 and 3 (p > 0.05). This difference was disappeared at following timepoints.
CONCLUSIONS: The release of TSH, FT3, FT4 and PRL were not inhibited and prophylactic thyroid hormone treatment was not required in VLBW infants receiving dopamine infusions.